Martin Christopher Nathan 4

What Happened

• Martin Christopher Nathan, a director of Edgewise Therapeutics (EWTX), received a grant of 16,377 stock options on June 5, 2026. The reported acquisition price is $0.00 (the filing treats this as a derivative award; no cash was paid at grant). The filing lists the transaction as an award/grant rather than a purchase or sale.

Key Details

• Transaction date: 2026-06-05; Filing date: 2026-06-16 (appears later than the typical Form 4 two-business-day reporting window).
• Grant details: 16,377 stock options, reported at $0.00 (derivative award).
• Vesting: Per the footnote, 100% of the options vest on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholders.
• Shares owned after the transaction: Not specified in the provided excerpt of the filing.
• Filing timeliness: The Form 4 was filed 11 days after the transaction date, which appears late relative to the usual two-business-day requirement.

Context

• This was a grant of stock options (an award), not an exercise or cash purchase. The options are subject to a one-year cliff vesting described above, so they are not immediately exercisable. Grants to directors are commonly part of routine compensation and do not, by themselves, indicate buying or selling intent.